Nonetheless, the broader effects of glucagon imbalance, especially in cases of α-cell overactivity and glucagon resistance, are still not fully understood in chronic conditions like type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), obesity, and hypertension. This evidence concerns the gene GCG and type 2 diabetes mellitus.